Myriad Genetics (MYGN) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $2.86 -46.74%
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
HFBL, PBHC, PBNK, More
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
HFBL, PBHC, PBNK, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.03, in-line with the analyst estimate of $0.03. Revenue for the quarter came in at $211 million versus the consensus estimate of $213.31 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Regency Centers (REG) Tops Q2 EPS by 2c
- Pathfinder Bancorp (PBHC) Tops Q2 EPS by 42c
- Contineum Therapeutics, Inc. (CTNM) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
